People: Safeguard Scientifics Inc (SFE)

SFE on New York Consolidated

19.89USD
23 Jul 2014
Price Change (% chg)

$0.16 (+0.81%)
Prev Close
$19.73
Open
$19.70
Day's High
$19.94
Day's Low
$19.70
Volume
26,435
Avg. Vol
92,834
52-wk High
$22.43
52-wk Low
$14.14

Search Stocks

Rosenthal, Robert 

Brief Biography

Dr. Robert (Bob) J. Rosenthal, Ph.D. is Independent Director of Safeguard Scientifics Inc. Dr. Rosenthal also is a director of Pathogenica, a director and Chairman of the Board of TraceBioAnalytics, and a director and Chairman of the Board of Sensorin. Positions held include Chairman of the Board and Chief Executive Officer of IMI Intelligent Medical Implants AG, a medical technology company that is developing an intelligent retinal implant system for degenerative retinal disorders (January 2010 to December 2012); President, Chief Executive Officer and a director of Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools (October 2005 to December 2009); President, Chief Executive Officer and a director of TekCel, Ltd., a provider of life sciences research tools (October 2003 to January 2007); President and Chief Executive Officer of Boston Life Sciences, Inc., a diagnostic and therapeutic development company (July 2002 to October 2003); President and Chief Executive Officer of Magellan Discovery Technologies, LLC, a life sciences acquisition company (January 2001 to July 2002); Senior Vice President of PerkinElmer Corporation and President of its instrument division (March 1999 to November 2000); and in various executive positions at Thermo Optek Corporation (September 1995 to February 1999). Dr. Rosenthal holds a BS degree from the University of Maryland, an MS degree from State University of New York, and a PhD degree from Emory University; completed a post-doctoral fellowship at, and was a guest scientist of the Alexander von Humboldt Foundation, followed by an additional post-doctoral fellowship at UCLA; and he holds an AEA Executive MBA degree from Stanford University. Dr. Rosenthal has 20 years of experience relating to companies involved in the development of diagnostics, therapeutics, medical devices, and life sciences tools.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Andrew Lietz

--

Stephen Zarrilli

1,773,600

Jeffrey McGroarty

641,177

Brian Sisko

1,061,460

Julie Dobson

--

Keith Jarrett

--
As Of 30 Dec 2013
Search Stocks